RESEARCH PLATFORM
FOR DRUG DEVELOPMENT

FIRST-IN-HUMAN DATA GENERATION

Our platform uses real ex vivo donor-derived adipose tissue models to mimic pathological conditions related to obesity and chronic metabolic diseases and generate first-in-human data to increase clinical success of novel drug candidates and pharmacological approaches.

For a paradigm shift in obesity research

Obesity is associated with chronic metabolic diseases, such as MASH, steatosis, type-2 diabetes and cardiovascular diseases. Despite the emergence of novel effective treatments in recent years, millions of people with obesity remain with no tailored therapeutic solution, in particular patients who are poorly responding to anti-obesity drugs.

In obesity, the balance between white adipose tissue (the ‘bad’ fat) and brown adipose tissue (the ‘good’ fat) is altered, with white adipose tissue accumulating and becoming dysfunctional, while brown adipose tissue disappears or is impaired. Brown adipose tissue is known for its energy expenditure capabilities and to regulate metabolism by secreting specific factors preventing chronic metabolic diseases.

Stimulating or restoring these natural beneficial properties of adipose tissue through 'browning' of white adipose tissue can have a profound impact on obesity management and pave the way for a comprehensive therapeutic approach for obesity.

A Breakthrough Technology for Chronic Metabolic Disorders and Obesity

ObAdEx is our breakthrough technology that overcomes the barrier of ex vivo culture and production of a viable and metabolically active adipose tissue

Our technology allows us to mimic ex vivo physio-pathological conditions of human adipose tissue associated to obesity and chronic metabolic diseases for a fine understanding of mechanisms of actions of lead drug candidates for these indications.

ObAdEx adipose tissue models are derived from donors and retain the donors' browning capacity, thus being a powerful tool to generate first-in-human ex vivo data for drug development targeting energy expenditure. Activation of energy expenditure potential in patients with obesity might indeed restore metabolic homeostasis, preventing and treating chronic metabolic diseases.

ObAdEx has received Deeptech label by BpiFrance and is being developed in collaboration with SATT Sud-Est, CNRS, Nice University Hospital and Côte d’Azur University/Idex.

2023

Early
development

2024

Process scale-up
& industrial adaptation

2025

Non-regulatory
preclinical

2026

Clinical batch &
Bridging studies

2027

First-in-patient
DARK CIRCLES,
PUFFY EYES, EYE BAGS
ExAdEx vascularized 3D adult organoid models obtained from freshly isolated subcutaneous adipose tissue allow to support claims related to vasoconstriction, vasodilation, stimulation of lymphatic network and drainage
ANTI-AGING, SKIN HEALTH,
TISSUE REGENERATION
ExAdEx donor-derived 3D inflammatory and fibrotic tissue models mimic complex skin interactions, allowing for claim substantiation of tissue remodeling, anti-stress, regenerative and anti-aging products
FAT BURNING,
METABOLIC ACTIVITY
ExAdEx 3D real fat tissue models are the only clinically relevant ex vivo models with physiological fat burning and browning capacity, supporting claims targeting weight management, cellulite and metabolic well-being